Conivaptan

Conivaptan

Skeletal formula of conivaptan
Space-filling model of conivaptan
Systematic (IUPAC) name
N-(4-((4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin- 6(1H)-yl)carbonyl)phenyl)- (1,1'-biphenyl)-2-carboxamide
Clinical data
Trade names	Vaprisol
AHFS/Drugs.com	monograph
Pregnancy category	US: C (Risk not ruled out)
Legal status	US: ℞-only
Routes of administration	intravenous
Pharmacokinetic data
Bioavailability	N/A
Identifiers
CAS Number	210101-16-9 Y
ATC code	C03XA02 (WHO)
PubChem	CID: 151171
IUPHAR/BPS	2203
DrugBank	DB00872 Y
ChemSpider	133239 Y
UNII	0NJ98Y462X Y
KEGG	D01236 N
ChEBI	CHEBI:681850 Y
ChEMBL	CHEMBL1755 Y
Chemical data
Formula	C32H26N4O2
Molecular mass	498.583 g/mol
SMILES O=C(c2ccccc2c1ccccc1)Nc3ccc(cc3)C(=O)N5c6c(c4nc(nc4CC5)C)cccc6
InChI InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37) Y Key:IKENVDNFQMCRTR-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Conivaptan (YM 087, brand name Vaprisol) is a non-peptide inhibitor of antidiuretic hormone (vasopressin receptor antagonist). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH), and there is some evidence it may be effective in heart failure. It is marketed by Cumberland Pharmaceuticals, Inc.

Conivaptan inhibits two of the three subtypes of the vasopressin receptor (V1a and V2). Effectively, it causes iatrogenic nephrogenic diabetes insipidus.

Conivaptan has not been approved by the FDA for the treatment of decompensated congestive heart failure. However, in theory, vasopressin receptor antagonism would be particularly useful in this setting, and an initial study shows that it has some promise.